COMMUNIQUÉS West-GlobeNewswire

The Crossing Recovery Appoints Jason C. Norbeck as Chief Addiction Counselor, Bringing Personal Experience and Expertise to Costa Mesa, CA
16/05/2025
Costa Mesa, CA, May 16, 2025 (GLOBE NEWSWIRE) -- The Crossing Recovery announces Jason C Norbeck as Chief Addiction Counselor. Jason holds an undergraduate degree from the University of Michigan and a Masters in [...]
75th Annual Regeneron International Science and Engineering Fair Awards Teen Scientists from Around the World More Than $9 Million in 2025 Competition
16/05/2025
Adam Kovalčík , 19, receives $100,000 Top Award for his development of a medicine that can stop viruses from copying genes and controlling infections at the world’s largest pre-college STEM competition in Columbus, Ohio [...]
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 30 avril 2025
16/05/2025
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 30 avril 2025 En application de l'article L. 233-8 II du code de commerce et de l'article 222-12-5 du règlement général de l'AMF, les [...]
SAFE - Lancement d’un regroupement d’actions Safe
16/05/2025
Lancement d’un regroupement d’actions Safe 1.000 actions anciennes contre 1 action nouvelle Mise en œuvre des opérations de regroupement à compter du 4 juin 2025 Premier jour de cotation des actions regroupées le 7 [...]
The Pennant Group Appoints Suzanne Snapper as Director
16/05/2025
EAGLE, Idaho, May 16, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, today announced the [...]
Novo Nordisk A/S: Lars Fruergaard Jørgensen to step down as CEO of Novo Nordisk
16/05/2025
Bagsværd, Denmark, 16 May 2025 – Novo Nordisk today announced changes to its executive leadership and Board of Directors. As per mutual agreement with the Novo Nordisk Board, Lars Fruergaard Jørgensen will step down [...]
Novo Nordisk A/S: Lars Fruergaard Jørgensen to step down as CEO of Novo Nordisk
16/05/2025
Bagsværd, Denmark, 16 May 2025 – Novo Nordisk today announced changes to its executive leadership and Board of Directors. As per mutual agreement with the Novo Nordisk Board, Lars Fruergaard Jørgensen will step down [...]
Paratek Pharmaceuticals to Present Clinical Data on NUZYRA® (omadacycline) at the American Thoracic Society (ATS) 2025 International Conference
16/05/2025
First conference presentations for: Phase 2b study for nontuberculous mycobacterial pulmonary disease (NTM PD) caused by Mycobacterium abscessus complex (MABc) Phase 3 OPTIC-2 study in moderate-to-severe community- [...]
Vaxart Approves Resolutions to Narrow Proposed Reverse Split Range and Proposes Reducing Authorized Shares at Future Stockholder Meeting
16/05/2025
Company Urges Stockholders to Vote ‘FOR’ Reverse Stock Split Proposal at Upcoming Annual Meeting to Avoid Nasdaq Delisting Leading Independent Proxy Advisory Firms, ISS and Glass Lewis, Support Proposal #2 SOUTH SAN [...]
Windtree Therapeutics Reports First Quarter 2025 Financial Results and Provides Key Business Updates
16/05/2025
WARRINGTON, Pa., May 16, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company and advancing early [...]
Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day
16/05/2025
WOBURN, Mass., May 16, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that it will [...]
Spectral Medical to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference
16/05/2025
TORONTO, May 16, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that [...]
PharmaTher Announces FDA Extends Review Period for Ketamine; New Approval Goal Date August 9, 2025
16/05/2025
TORONTO, May 16, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) ("PharmaTher" or the "Company"), a specialty pharmaceutical company focused on ketamine for unmet medical needs, today [...]
Vivex Biologics, Inc. Executive Chair Nominated for Ernst & Young LLP Entrepreneur of the Year® 2025 Florida Award
16/05/2025
MIAMI, May 16, 2025 (GLOBE NEWSWIRE) -- Vivex Biologics, Inc., a leader in developing and delivering innovative allografts, today announced the company’s Executive Chairman, John A. McCallum, has been selected as a [...]
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
16/05/2025
SOUTH SAN FRANCISCO, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best- [...]
QHSLab, Inc. Signals Strategic Debt Restructuring to Strengthen Balance Sheet and Drive Growth
16/05/2025
Company in Advanced Discussions to Restructure Convertible Debt and Unlock Shareholder Value Potential Agreement Expected to Improve Financial Flexibility and Reduce Dilution Pressure WEST PALM BEACH, FL, May 16, 2025 ( [...]
Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study
16/05/2025
Company intends to provide an interim read out by the end of summer 2025 Top-line results anticipated in Q4 2025; study on track to support U.S. pivotal trial initiation in 2026 BERKELEY, Calif. and MAINZ, Germany, May [...]
Conduit Pharmaceuticals Inc. Announces Reverse Stock Split
16/05/2025
NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 16, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a dynamic, multi-asset clinical stage, life science company [...]
FibroBiologics Presents at the Society for Investigative Dermatology Annual Meeting
16/05/2025
HOUSTON, May 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending with a focus on the development of [...]

Pages